Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Investigation of CD36 Induced Anti-Angiogenic Response via Proximity Biotinylation
EF 2021-22
Résumé
With cancer rates rising globally, research needs to develop effective treatments that reduce mortality and suffering associated with these devastating diseases. When tumor cells are deprived of oxygen, they manipulate the environment to develop new blood vessels. These blood vessels provide tumors with the oxygen and nutrients needed for growth and a pathway to spread to other parts of the body. Cancer therapies blocking tumor blood vessel growth have been developed, however, clinical studies have shown that these treatments are only temporarily effective. To improve the effectiveness of cancer therapies, further research is needed better understand the signaling pathways preventing blood vessel development.
CD36 is a receptor that is found in cells lining blood vessels - endothelial cells. CD36 binding to a protein called thrombospondin-1 activates a signaling pathway resulting in the death of endothelial cells. Despite its relevance to cancer, the CD36 signaling pathway is poorly characterized. Given the small size of CD36, we believe that additional proteins are necessary for its signaling. In my M.Sc, I will identify and investigate the role of these necessary proteins.
Super-resolution microscopy will be critical in visualizing and determining the composition of the small CD36 signaling complexes. Reducing the expression of candidate proteins within cells and analyzing the effect on signaling will provide information on the role of these candidate proteins. The investigation of the CD36 signaling pathway will unveil regulators and targets that will enhance and influence the development of new cancer therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466502
Name
Saini Arashdeep S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigation of CD36 Induced Anti-Angiogenic Response via Proximity Biotinylation
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Angiogenic Signaling; Biotinylation; Cancer; Mass Spectrometry; Membrane Organization; Receptor Clustering; Super-Resolution Microscopy
Abstract
With cancer rates rising globally, research needs to develop effective treatments that reduce mortality and suffering associated with these devastating diseases. When tumor cells are deprived of oxygen, they manipulate the environment to develop new blood vessels. These blood vessels provide tumors with the oxygen and nutrients needed for growth and a pathway to spread to other parts of the body. Cancer therapies blocking tumor blood vessel growth have been developed, however, clinical studies have shown that these treatments are only temporarily effective. To improve the effectiveness of cancer therapies, further research is needed better understand the signaling pathways preventing blood vessel development.
CD36 is a receptor that is found in cells lining blood vessels - endothelial cells. CD36 binding to a protein called thrombospondin-1 activates a signaling pathway resulting in the death of endothelial cells. Despite its relevance to cancer, the CD36 signaling pathway is poorly characterized. Given the small size of CD36, we believe that additional proteins are necessary for its signaling. In my M.Sc, I will identify and investigate the role of these necessary proteins.
Super-resolution microscopy will be critical in visualizing and determining the composition of the small CD36 signaling complexes. Reducing the expression of candidate proteins within cells and analyzing the effect on signaling will provide information on the role of these candidate proteins. The investigation of the CD36 signaling pathway will unveil regulators and targets that will enhance and influence the development of new cancer therapies.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Saini, Arashdeep S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~